NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS NOT A PROSPECTUS AS DEFINED BY REGULATION (EU) NO. 2017/1129 OF JUNE 14, 2017 AND DOES NOT CONSTITUTE A PUBLIC OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
Company announcement
No. 03/2024 - Inside Information
Contemplated Rights Issue
The Company intends to strengthen its capital structure by an issuance of new shares with pre-emptive rights for
A prospectus is being prepared by the Company and will be published in connection with the launch of the Rights Issue. The prospectus is subject to approval by the
A number of the Company's large shareholders have expressed their support for the process and provided positive feedback with respect to their participation in the Rights Issue.
Furthermore, certain members of the Company's Board of Directors and Executive Management holding shares in the Company have expressed their intention to exercise their pre-emptive rights in the Rights Issue.
The launch of the Rights Issue will be subject to a number of conditions, including among others an authorization for the Board of Directors of the Company to increase the share capital proposed to be granted at an extraordinary general meeting (the "EGM") to be held later in
Extraordinary general meeting
Later today, the Company will convene the EGM to be held on
The EGM agenda, full proposal, and applicable deadlines will follow in a separate announcement.
Expected key dates for the Rights Issue
The key dates for the Rights Issue are expected to be as follows (subject to change and assuming the launch and successful completion of the Rights Issue).
Event | Date |
Publication of prospectus | |
Last trading day in the shares including pre-emptive rights | |
First day of trading in the shares excluding pre-emptive rights | |
Rights trading period commences | |
Allocation time of pre-emptive rights | |
Subscription period for the new shares commences | |
Rights trading period closes | |
Subscription period for the new shares closes | |
Expected publication of the results of the Rights Issue | |
Allocation of new shares not subscribed for by exercise of pre-emptive rights | |
Expected completion of the Rights Issue, including settlement of the new shares | |
First day of trading and official listing of the new shares on Nasdaq Copenhagen |
Updated financial calendar
To align with the Rights Issue process, the Company has updated its financial calendar for the financial year ending
Publication of the Company's annual report for the financial year ended
The updated financial calendar for FY2024:
Event | Date |
Extraordinary general meeting | |
Publication of annual report for FY2023 | |
Call on annual report for FY2023 | |
Expected publication of prospectus relating to Rights Issue | |
Annual general meeting | |
Trading statement for Q1 FY2024 | |
Half-year interim report for FY2024 | |
Trading statement for Q3 2024 |
Advisers in the Rights Issue
For further information, please contact:
+45 25 63 39 90, investorrelations@aquaporin.com
About
Important disclaimer
This announcement does not constitute an offering memorandum or a prospectus as defined by Regulation (EU) No. 2017/1129 of
The information contained in this announcement is for background purposes only and does not purport to be full or complete. This announcement has not been approved by any competent regulatory authority. The information in this announcement is subject to change. No obligation is undertaken to update this announcement or to correct any inaccuracies except as required by applicable laws, and the distribution of this announcement shall not be deemed to be any form of commitment on the part of the Company to proceed with any transaction or arrangement referred to herein. This announcement is intended for the sole purpose of providing information. Persons needing advice should consult an independent financial adviser. This announcement does not constitute an investment recommendation. The price and value of securities and any income from them can go down as well as up and you could lose your entire investment. Past performance is not a guide to future performance. Information in this announcement cannot be relied upon as a guide to future performance.
None of the Company or any of its respective subsidiary undertakings, affiliates or any of their respective directors, officers, employees, advisers, agents or any other person accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to the truth, accuracy, completeness or fairness of the information or opinions in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.
This announcement does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any shares or any other securities nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with or act as an inducement to enter into, any contract or commitment whatsoever. The potential transactions described in this announcement and the distribution of this announcement and other information in connection with the potential transactions in certain jurisdictions may be restricted by law and persons into whose possession this announcement, any document or other information referred to herein comes should inform themselves about, and observe, any such restrictions.
In particular, this announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in
The securities referred to in this announcement have not been, and will not be, registered under the
The information set forth in this announcement is only being distributed to, and directed at, persons in Member States of the EEA who are qualified investors ("
In addition, in the
Forward-looking statements
Matters discussed in this company announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as "believe", "expect", "anticipate", "intend", "estimate", "will", "may", "continue", "should", and similar expressions, as well as other statements regarding future events or prospects. Specifically, this company announcement includes information with respect to projections, estimates, and targets that also constitute forward-looking statements. The forward-looking statements in this company announcement are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies, and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, and other important factors include, among others: Limited experience in commercialization of the Company's products, failure to successfully implement strategies, dependence on third parties for manufacturing certain product components and the supply of certain raw materials, manufacturing disruptions, strategic collaboration, protection of the Company's intellectual property rights and other risks disclosed in
https://news.cision.com/aquaporin-a-s/r/update-on-rights-issue-process--extraordinary-general-meeting--and-financial-calendar,c3938008
https://mb.cision.com/Main/22362/3938008/2637524.pdf
https://news.cision.com/aquaporin-a-s/i/071119-aquaporin-00867-sh,c3272872
(c) 2024 Cision. All rights reserved., source